P3 Reports Q4 Net Loss of $165.7 Million
Q4 net loss was $165.7M vs. loss of $129.1M last year. "2025 was a year of meaningful progress in repositioning the business. We strengthened our contract economics, improved provider alignment, and built a more disciplined operating foundation. With that work in place, we enter 2026 with a clear path to profitability and approximately $170 million of expected year-over-year EBITDA improvement at the midpoint of our guidance range," said Aric Coffman, CEO of P3. "Additionally, our new Medicare Advantage geography reflects our approach to smart growth with a deliberate glidepath toward full risk that we believe will strengthen the long-term earnings power of the platform."
Trade with 70% Backtested Accuracy
Analyst Views on PIII
About PIII
About the author
P3 Health Partners Q4 Earnings Report Analysis
- Earnings Performance: P3 Health Partners reported a Q4 GAAP EPS of -$23.02, missing expectations by $13.56, indicating ongoing challenges in profitability that may negatively impact investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $384.8M, a staggering 1153.4% increase year-over-year, exceeding expectations by $27.15M, demonstrating strong market demand despite a slight decline from last year's $1.50B total revenue.
- Medical Margin Improvement: The medical margin stood at $23.5M, or $17 PMPM, with normalized medical margin at $53.4M, reflecting progress in cost control and service efficiency, although the net loss reached $323.1M.
- Future Guidance: For 2026, adjusted EBITDA is expected to range from -$20M to $40M, with a midpoint of $10M, indicating a projected year-over-year improvement of approximately $170M, showcasing management's confidence in future profitability.
P3 Health Partners Inc. Projects Total Revenue Between $1.5 Billion and $1.7 Billion for 2026
- Revenue Guidance: Health Partners Inc. has provided a total revenue guidance range for 2026, estimating between $1.5 billion and $1.7 billion.
P3 Health Partners Reports Results for Fourth Quarter and Full Year 2025
Fourth Quarter Results: Health Partners has announced its results for the fourth quarter of 2025, highlighting key financial and operational metrics.
Full Year Performance: The organization also provided a comprehensive overview of its performance for the entire year of 2025, showcasing growth and achievements.
P3 Health Partners to Release 2025 Financial Results on March 26, 2026
- Earnings Release Announcement: P3 Health Partners Inc. plans to release its financial results for the fourth quarter and full year 2025 on March 26, 2026, reflecting the company's ongoing growth in healthcare management.
- Conference Call Details: Management will host a conference call at 1:30 PM PT (4:30 PM ET) on the same day to discuss the financial results, enhancing communication with investors.
- Live Webcast: The conference call will be webcast live in the 'Events & Presentations' section of P3's website, ensuring investors can access the latest company updates in real-time.
- Investor Relations Support: P3 Health Partners will provide an archived recording of the webcast for 90 days post-conference, further supporting investors' understanding and analysis of the company's performance.
P3 Health Partners Forms Joint Venture with Commonwealth to Expand Value-Based Care
- Joint Venture Formation: P3 Health Partners and Commonwealth Primary Care ACO have established a Joint Venture Management Services Organization aimed at expanding value-based care support across Arizona, California, Nevada, Oregon, and North Carolina, enhancing service capabilities for primary care physicians.
- Market Expansion: This partnership expands P3's footprint into Maricopa County, Arizona, further solidifying its position in a key growth market, which is expected to drive business growth in the region.
- Operational Efficiency Improvement: The joint venture combines P3's strengths in Medicare Advantage and ACO with Commonwealth's ACO REACH program to create a unified operational platform, thereby enhancing performance and efficiency in healthcare delivery.
- Physician Support Enhancement: The joint venture will strengthen support for independent primary care physicians by sharing operations and best practices, ensuring they can thrive and deliver exceptional care in a value-based environment.
Projected Target Price for ONEQ Analyst: $104
ETF Performance Analysis: The Fidelity Nasdaq Composite Index ETF (ONEQ) has an implied analyst target price of $103.84, indicating a potential upside of 10.75% from its current trading price of $93.76.
Notable Holdings: Key underlying holdings with significant upside potential include KODIAK ROBOTICS INC (KDK), Red Cat Holdings Inc (RCAT), and P3 Health Partners Inc (PIII), with expected price increases of 96.58%, 62.44%, and 58.15% respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
P3 Health Partners Q4 Earnings Report Analysis
- Earnings Performance: P3 Health Partners reported a Q4 GAAP EPS of -$23.02, missing expectations by $13.56, indicating ongoing challenges in profitability that may negatively impact investor confidence.
- Revenue Surge: The company achieved Q4 revenue of $384.8M, a staggering 1153.4% increase year-over-year, exceeding expectations by $27.15M, demonstrating strong market demand despite a slight decline from last year's $1.50B total revenue.
- Medical Margin Improvement: The medical margin stood at $23.5M, or $17 PMPM, with normalized medical margin at $53.4M, reflecting progress in cost control and service efficiency, although the net loss reached $323.1M.
- Future Guidance: For 2026, adjusted EBITDA is expected to range from -$20M to $40M, with a midpoint of $10M, indicating a projected year-over-year improvement of approximately $170M, showcasing management's confidence in future profitability.
P3 Health Partners Inc. Projects Total Revenue Between $1.5 Billion and $1.7 Billion for 2026
- Revenue Guidance: Health Partners Inc. has provided a total revenue guidance range for 2026, estimating between $1.5 billion and $1.7 billion.
P3 Health Partners Reports Results for Fourth Quarter and Full Year 2025
Fourth Quarter Results: Health Partners has announced its results for the fourth quarter of 2025, highlighting key financial and operational metrics.
Full Year Performance: The organization also provided a comprehensive overview of its performance for the entire year of 2025, showcasing growth and achievements.
P3 Health Partners to Release 2025 Financial Results on March 26, 2026
- Earnings Release Announcement: P3 Health Partners Inc. plans to release its financial results for the fourth quarter and full year 2025 on March 26, 2026, reflecting the company's ongoing growth in healthcare management.
- Conference Call Details: Management will host a conference call at 1:30 PM PT (4:30 PM ET) on the same day to discuss the financial results, enhancing communication with investors.
- Live Webcast: The conference call will be webcast live in the 'Events & Presentations' section of P3's website, ensuring investors can access the latest company updates in real-time.
- Investor Relations Support: P3 Health Partners will provide an archived recording of the webcast for 90 days post-conference, further supporting investors' understanding and analysis of the company's performance.
P3 Health Partners Forms Joint Venture with Commonwealth to Expand Value-Based Care
- Joint Venture Formation: P3 Health Partners and Commonwealth Primary Care ACO have established a Joint Venture Management Services Organization aimed at expanding value-based care support across Arizona, California, Nevada, Oregon, and North Carolina, enhancing service capabilities for primary care physicians.
- Market Expansion: This partnership expands P3's footprint into Maricopa County, Arizona, further solidifying its position in a key growth market, which is expected to drive business growth in the region.
- Operational Efficiency Improvement: The joint venture combines P3's strengths in Medicare Advantage and ACO with Commonwealth's ACO REACH program to create a unified operational platform, thereby enhancing performance and efficiency in healthcare delivery.
- Physician Support Enhancement: The joint venture will strengthen support for independent primary care physicians by sharing operations and best practices, ensuring they can thrive and deliver exceptional care in a value-based environment.
Projected Target Price for ONEQ Analyst: $104
ETF Performance Analysis: The Fidelity Nasdaq Composite Index ETF (ONEQ) has an implied analyst target price of $103.84, indicating a potential upside of 10.75% from its current trading price of $93.76.
Notable Holdings: Key underlying holdings with significant upside potential include KODIAK ROBOTICS INC (KDK), Red Cat Holdings Inc (RCAT), and P3 Health Partners Inc (PIII), with expected price increases of 96.58%, 62.44%, and 58.15% respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
